<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Stable COPD: Initial pharmacologic management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Stable COPD: Initial pharmacologic management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Stable COPD: Initial pharmacologic management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary T Ferguson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barry Make, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James K Stoller, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic obstructive pulmonary disease (COPD) is a common condition with high morbidity and mortality, affecting males and females equally. It is estimated that approximately 10 percent of individuals aged 40 years or older have COPD, although the prevalence varies between countries and increases with age [
         <a href="#rid1">
          1-3
         </a>
         ]. COPD is a leading cause of death among adults, both in the United States and worldwide [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         The initial pharmacologic management of stable COPD will be reviewed here. The clinical manifestations, diagnosis, comorbidities, monitoring, and prognosis of COPD, an overview of COPD management, and the management of refractory COPD and acute exacerbations of COPD are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">
          "Chronic obstructive pulmonary disease: Diagnosis and staging"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1439.html" rel="external">
          "Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1443.html" rel="external">
          "Chronic obstructive pulmonary disease: Risk factors and risk reduction"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/120326.html" rel="external">
          "Stable COPD: Overview of management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">
          "Management of refractory chronic obstructive pulmonary disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">
          "COPD exacerbations: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120055">
          (Related Pathway(s):
          <a class="utd-content-120055" href="/pathway/120055?topicRef=1447&amp;source=see_link">
           Chronic obstructive pulmonary disease: Severity assessment and selection of initial therapy in adults
          </a>
          .)
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          ASSESSING DISEASE PATTERN AND SEVERITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A multicomponent assessment system has been developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to guide initiation of therapy for COPD [
         <a href="#rid6">
          6
         </a>
         ]. The GOLD system categorizes patients primarily based on assessment of symptoms and risk of future exacerbations and hospitalizations. We support this approach to initial management.
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120055">
          (Related Pathway(s):
          <a class="utd-content-120055" href="/pathway/120055?topicRef=1447&amp;source=see_link">
           Chronic obstructive pulmonary disease: Severity assessment and selection of initial therapy in adults
          </a>
          .)
         </span>
        </p>
        <p class="headingAnchor" id="H2496529843">
         <span class="h2">
          Symptoms and risk of exacerbations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with COPD may be classified according to symptoms and exacerbation history into three groups (A, B, and E)  (
         <a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ]. Symptoms should be assessed using a validated instrument, such as the modified Medical Research Council (mMRC) dyspnea scale (
         <a class="calc calc_professional" href="/z/d/html/142813.html" rel="external">
          calculator 1
         </a>
         ) or the COPD assessment Test (CAT) (
         <a class="calc calc_professional" href="/z/d/html/142838.html" rel="external">
          calculator 2
         </a>
         ) [
         <a href="#rid6">
          6-9
         </a>
         ]. For patients newly initiating therapy, exacerbation risk should be determined based on the patient’s history of exacerbations and their severity in the past year; two or more exacerbations requiring systemic glucocorticoids or one or more COPD hospitalizations indicate a greater risk of future exacerbations [
         <a href="#rid6">
          6,10,11
         </a>
         ]. After initiation of pharmacologic therapy, even less frequent exacerbations may make a significant impact on escalation of therapy, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Exacerbation history'
         </a>
         .)
        </p>
        <p>
         The symptom and risk components are combined to categorize patients into one of three groups as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group A: Less symptomatic, low risk of future exacerbations:
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         mMRC grade 0 to 1 or CAT score &lt;10
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Zero to one exacerbation per year without hospitalization
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group B: More symptomatic, low risk of future exacerbations:
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         mMRC grade ≥2 or CAT score ≥10
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Zero to one exacerbation per year without hospitalization
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group E: High risk of future exacerbations:
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ≥2 exacerbations per year or ≥1 hospitalization for exacerbation
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3058653337">
         <span class="h2">
          Airflow limitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the severity of the decrement in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) is inversely associated with COPD exacerbation risk, FEV
         <sub>
          1
         </sub>
         is inferior to exacerbation history in predicting risk of future exacerbations for individual patients [
         <a href="#rid12">
          12
         </a>
         ]. For this reason, FEV
         <sub>
          1
         </sub>
         is not included in the ABE groups [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         We use spirometry to confirm the diagnosis of COPD, assess airflow limitation severity, and to calculate the Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity (BODE) index (
         <a class="calc calc_professional" href="/z/d/html/13448.html" rel="external">
          calculator 3
         </a>
         ), which remains a useful measure to assess risk of death or hospitalization due to COPD. As an objective measure of physiologic limitation, spirometry is also essential in other areas of COPD care, including disease progression, consideration of alternate diagnoses, surgical risk stratification and assessment for lung volume reduction, and other invasive interventions. (See
         <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">
          "Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Assessment of severity and staging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3691933276">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacologic therapy for COPD should always be employed along with nonpharmacologic management. (See
         <a class="medical medical_review" href="/z/d/html/120326.html" rel="external">
          "Stable COPD: Overview of management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">
          "Pulmonary rehabilitation"
         </a>
         .)
        </p>
        <p>
         We share the philosophy of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) that the aim of therapy is to improve patient symptoms, decrease exacerbations, and improve patient function and quality of life [
         <a href="#rid6">
          6
         </a>
         ]. The initial selection of a pharmacologic agent is based on the severity of symptoms and risk of future exacerbations  (
         <a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">
          algorithm 1
         </a>
         ); therapy is adjusted at follow-up visits based on the clinical response to current therapy. (See
         <a class="local">
          'Symptoms and risk of exacerbations'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management"
         </a>
         .)
        </p>
        <p>
         The mainstays of drug therapy for stable symptomatic COPD are inhaled bronchodilators (beta-agonists and muscarinic antagonists). These agents are most commonly given in combination with or without the addition of inhaled glucocorticoids; patients with less severe symptoms and low exacerbation risk may also receive inhaled bronchodilators individually  (
         <a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef122795" href="/z/d/graphic/122795.html" rel="external">
          table 1
         </a>
         ). Inhaled bronchodilators are generally administered via handheld inhalation in the form of metered dose, soft mist, or dry powder inhalers, although some patients may benefit from therapy administered by nebulization (eg,
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">
          formoterol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9433" href="/z/d/drug information/9433.html" rel="external">
          arformoterol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         ,
         <a class="drug drug_general" data-topicid="119622" href="/z/d/drug information/119622.html" rel="external">
          revefenacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         ).
        </p>
        <p>
         While we believe the GOLD approach appropriately focuses on targeting therapies based on symptoms and exacerbation risk, the separation of patients into the "ABE" groups is based largely on post hoc analyses and we await rigorous prospective studies. Some patients with very severe disease may require initiation of multiple medications simultaneously to achieve symptom and exacerbation control rather than employing a stepwise approach. Additional study of specific COPD groups may yield better evidence to support initial treatment approaches.
        </p>
        <p class="headingAnchor" id="H2117482194">
         <span class="h1">
          RESCUE BRONCHODILATOR THERAPY FOR ALL PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients with COPD, we prescribe a short-acting bronchodilator to use as needed for relief of episodic dyspnea and early treatment of exacerbations. We typically use a short-acting beta-agonist (SABA) in most patients because short-acting muscarinic antagonists (SAMAs) are generally not recommended to be used in those also prescribed long-acting muscarinic antagonist (LAMA) therapy. For patients receiving long-acting beta-agonists (LABAs) without LAMA coadministration or who only use short-acting agents, we prefer combination SABA-SAMA therapy because this achieves a greater bronchodilator response than either agent alone [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rescue therapy in patients taking long-acting muscarinic antagonists
         </strong>
         – SAMAs are generally not recommended to be used routinely in conjunction with LAMAs due to cumulative anticholinergic side effects and theoretical blockage of LAMA effects by the SAMA. For the majority of patients with COPD who are also on LAMA therapy, SABAs are prescribed for relief of episodic worsening of dyspnea, such as associated with triggers and exacerbations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Short-acting inhaled beta-agonists include
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         and
         <a class="drug drug_general" data-topicid="10215" href="/z/d/drug information/10215.html" rel="external">
          levalbuterol
         </a>
         . They have been proven in randomized trials and meta-analyses to improve symptoms and lung function acutely in stable COPD [
         <a href="#rid14">
          14
         </a>
         ]. However, SABA therapy is prescribed only on an as-needed basis for those with intermittent symptoms, rather than regularly scheduled, to decrease sympathomimetic exposure. Patients requiring frequent use should transition to long-acting agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One trial randomly assigned 53 patients with COPD to receive regularly scheduled
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         or placebo, while continuing regular SAMA therapy, inhaled glucocorticoid, and as-needed albuterol [
         <a href="#rid15">
          15
         </a>
         ]. Regularly scheduled albuterol doubled the total amount of albuterol received without a clinically significant impact on lung function, symptoms, or exercise capacity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although inhaled SABAs are generally felt to be safe when used at the recommended doses, side effects and toxicity can occur. Because most recommended doses of SABAs result in less than maximal achievable bronchodilation, patients frequently use multiple doses in the setting of severe breathlessness. Symptoms of SABA overuse include tremor and tachycardia, which is due to a combination of chronotropism and peripheral arterial dilation. Hypokalemia can also occur in extreme cases and should be monitored in patients at risk. Large trials have not demonstrated an increase in serious cardiac arrhythmias with typical use. (See
         <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">
          "Causes of hypokalemia in adults", section on 'Elevated beta-adrenergic activity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1437.html" rel="external">
          "Management of the patient with COPD and cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1454.html" rel="external">
          "Arrhythmias in COPD", section on 'Beta-adrenergic agonists'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Oral SABAs are generally avoided when possible because of a higher incidence of side effects and reduced efficacy as bronchodilators.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rescue therapy for patients not taking long-acting muscarinic antagonists
         </strong>
         – In patients not coadministered LAMAs, we prefer SABA-SAMA therapy for rescue because of increased bronchodilator effectiveness compared with either short-acting agent alone. In addition, using low doses of both agents avoids side effects associated with use of a high-dose single agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Like SABAs, SAMAs are inhaled bronchodilators that result in a relatively short-term, pharmacologically mediated improvement in lung function that reverses with cessation of therapy. When used alone as a rescue therapy, the usual dose of the SAMA
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         is two inhalations (17 mcg/actuation via metered dose inhaler [MDI]) four to six times per day as needed. Ipratropium can also be prescribed via nebulization (0.5 mg/2.5 mL vial) at a dose of one vial every four to eight hours as needed. As-needed and regularly scheduled dosing regimens of SAMAs have not been compared. (See
         <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">
          "Role of muscarinic antagonist therapy in COPD"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individually,
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         and
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         have been compared in randomized trials [
         <a href="#rid13">
          13,16,17
         </a>
         ]. On average, both medications improve lung function to a similar degree, although the effects may vary [
         <a href="#rid18">
          18
         </a>
         ]. Side effects are unique to each medication class but are minimal at commonly prescribed doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The combination of
         <a class="drug drug_general" data-topicid="8772" href="/z/d/drug information/8772.html" rel="external">
          ipratropium-albuterol
         </a>
         (20 mcg/100 mcg per actuation) in a soft mist inhaler (SMI) can be administered one inhalation every four to six hours as needed. The solution for nebulization (
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         0.5 mg-albuterol 2.5 mg per 3 mL vial) can be administered as one vial every four to six hours as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The degree of bronchodilation achieved by SABAs and muscarinic antagonists is larger than either agent alone when typically recommended (submaximal) doses of each agent are combined [
         <a href="#rid6">
          6,13,17
         </a>
         ]. As an example, one trial randomly assigned 534 patients with COPD to receive
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         alone,
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         alone, or combination therapy (albuterol plus ipratropium) [
         <a href="#rid13">
          13
         </a>
         ]. Combination therapy increased the mean peak forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) more than either agent alone but did not alter exacerbation frequency. A similar study reported that combination therapy decreased exacerbation rates compared with albuterol, but not ipratropium [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H242460947">
         <span class="h1">
          LESS SYMPTOMATIC PATIENTS AT LOW RISK OF EXACERBATION (GROUP A)
         </span>
        </p>
        <p class="headingAnchor" id="H2635435886">
         <span class="h2">
          Choice of long-acting bronchodilator agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to short-acting bronchodilator rescue therapy, we suggest that Group A patients use a long-acting bronchodilator  (
         <a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">
          algorithm 1
         </a>
         ). Long-acting bronchodilators have been shown to be effective even in patients with mild symptoms and low baseline exacerbation rates.
        </p>
        <p>
        </p>
        <p>
         For example, in a placebo-controlled trial of 841 patents with minimally symptomatic COPD (forced expiratory volume in one second [FEV
         <sub>
          1
         </sub>
         ] ≥50 percent predicted) patients receiving
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         daily demonstrated a decrease in yearly exacerbation rates (0.27 versus 0.50 events per patient-year; risk ratio 0.53, 95% CI 0.39-0.73) and an increase in FEV
         <sub>
          1
         </sub>
         (between group difference 157 mL [95% CI, 123-192]) [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Either a long-acting beta-agonist (LABA) or a long-acting muscarinic antagonist (LAMA; also known as long-acting anticholinergic agent) is acceptable for patients with Group A COPD [
         <a href="#rid6">
          6
         </a>
         ]. In our clinical practice, we prefer a LAMA to a LABA based on evidence of modestly increased efficacy in preventing exacerbations [
         <a href="#rid20">
          20-24
         </a>
         ]. However, a once daily LABA is a reasonable alternative depending on the patient’s symptoms, comorbidities, and potential medication adverse effects.
        </p>
        <p>
         The efficacy and safety of LABAs and LAMAs have been compared in meta-analyses and randomized trials [
         <a href="#rid20">
          20,21,25,26
         </a>
         ]; most of the research has involved
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         as the LAMA. Overall efficacy and safety appear comparable in terms of symptom control. Both LAMAs and LABAs reduce exacerbations, but LAMAs have a greater effect [
         <a href="#rid20">
          20-22
         </a>
         ].
        </p>
        <p>
         Individual patients may prefer one bronchodilator over the other. As an example, some patients may experience a resting tachycardia or somatic tremor with LABA therapy and therefore prefer a LAMA. Alternatively, LAMAs can be associated with dry mouth that can be bothersome; rinsing the mouth after use may reduce this effect. Symptoms of urinary retention have occasionally been reported with LAMA, so a LABA may be preferred for patients at high risk for urinary retention. (See
         <a class="medical medical_review" href="/z/d/html/1454.html" rel="external">
          "Arrhythmias in COPD", section on 'Beta-adrenergic agonists'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">
          "Role of muscarinic antagonist therapy in COPD", section on 'Potential risks'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comparative efficacy
         </strong>
         – A meta-analysis that included seven trials (12,223 participants) compared
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         with various LABAs (
         <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">
          salmeterol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">
          formoterol
         </a>
         , and
         <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">
          indacaterol
         </a>
         ) [
         <a href="#rid21">
          21
         </a>
         ]. No significant difference was noted in improvements in quality of life or dyspnea between tiotropium and the various LABAs. Tiotropium was more effective at reducing exacerbations (odds ratio [OR] 0.86, 95% CI 0.79-0.93). However, no statistically significant differences were noted in overall hospitalizations or mortality. The meta-analysis concluded that the small number of studies and variability (heterogeneity) in the results prevented determination of which agent would lead to a greater long-term benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a subsequent trial of 3444 patients with severe COPD and at least one exacerbation in the previous year,
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         and
         <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">
          indacaterol
         </a>
         yielded similar improvements in FEV
         <sub>
          1
         </sub>
         , but tiotropium provided better protection against exacerbations over the next year than indacaterol (0.61 versus 0.79 exacerbations, rate ratio 0.76, 95% CI 0.68-0.87) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comparison of adverse cardiovascular effects
         </strong>
         – LABAs and LAMAs are associated with similar rates of adverse cardiovascular events. The data on cardiovascular side effects of individual agents are covered elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1454.html" rel="external">
          "Arrhythmias in COPD", section on 'Beta-adrenergic agonists'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1437.html" rel="external">
          "Management of the patient with COPD and cardiovascular disease", section on 'Beta-2 agonists'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">
          "Role of muscarinic antagonist therapy in COPD", section on 'Cardiovascular effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The best comparative data come from a trial of 1683 patients with COPD randomly assigned to receive
         <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">
          indacaterol
         </a>
         150 or 300 mcg, placebo, or open-label
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         once daily [
         <a href="#rid27">
          27
         </a>
         ]. The incidence of adverse events, such as low serum potassium, high blood glucose, cardiac events, and prolonged QTc interval was similar across treatments.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, a large case-control analysis found similar small increases in the likelihood of hospitalizations or emergency department visits for cardiovascular events associated with new LABA or LAMA prescriptions compared with those not prescribed these agents (adjusted odds ratios 1.31 [95% CI 1.12-1.52] and 1.14 [1.01-1.28], respectively) [
         <a href="#rid28">
          28
         </a>
         ]. No significant differences were noted between the two classes of bronchodilators. The noted increased short-term risk of bronchodilator prescriptions, however, must be interpreted in the context of likely confounding by susceptibility or disease severity. The cardiovascular safety of individual long-acting bronchodilators is largely reassuring based on postapproval monitoring and clinical trials, which are discussed in detail separately.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3461365121">
         <span class="h2">
          Dosing and efficacy of individual agents
         </span>
        </p>
        <p class="headingAnchor" id="H1600532055">
         <span class="h3">
          Long-acting beta-agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         LABAs include
         <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">
          salmeterol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">
          formoterol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9433" href="/z/d/drug information/9433.html" rel="external">
          arformoterol
         </a>
         ,
         <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">
          indacaterol
         </a>
         , vilanterol, and
         <a class="drug drug_general" data-topicid="96482" href="/z/d/drug information/96482.html" rel="external">
          olodaterol
         </a>
         ; all are beta-2 selective  (
         <a class="graphic graphic_table graphicRef122116" href="/z/d/graphic/122116.html" rel="external">
          table 2
         </a>
         ). Arformoterol is only available as a solution for nebulization; vilanterol is only available as a component of a combination product with a LAMA. Multiple studies have demonstrated the benefit of LABAs in patients with stable COPD [
         <a href="#rid29">
          29-37
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">
          Salmeterol
         </a>
         – Salmeterol is the most commonly used and well-studied stand-alone LABA and is administered by dry powder inhaler (50 mcg/actuation) one inhalation twice daily. It has a slow onset (120 minutes) with intermediate duration [
         <a href="#rid38">
          38
         </a>
         ]. The largest trial of salmeterol, Toward a Revolution in COPD Health (TORCH), randomly assigned 6112 patients with mostly severe airflow limitation (mean FEV
         <sub>
          1
         </sub>
         44 percent of predicted) to one of four treatment arms for three years: salmeterol alone (50 mcg twice daily),
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         alone (500 mcg twice daily), combination therapy (salmeterol plus fluticasone), or placebo [
         <a href="#rid33">
          33
         </a>
         ]. Salmeterol significantly decreased exacerbation rates and improved lung function compared with placebo. Although not designed to evaluate survival, the study found no increase in mortality with salmeterol compared with placebo, supporting the safety of this LABA in COPD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">
          Formoterol
         </a>
         <strong>
          and
         </strong>
         <a class="drug drug_general" data-topicid="9433" href="/z/d/drug information/9433.html" rel="external">
          arformoterol
         </a>
         – Formoterol is a twice daily LABA with a rapid onset (time to onset of bronchodilation within three minutes) and intermediate duration of action [
         <a href="#rid37">
          37,39
         </a>
         ]. It is available as a single agent dry powder inhaler in Canada and Europe. In the United States, it is available as a solution for nebulization (20 mcg/2 mL vial, one vial twice daily) and as a component in combination LAMA-LABA and LABA-glucocorticoid inhalers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9433" href="/z/d/drug information/9433.html" rel="external">
          Arformoterol
         </a>
         is available as a solution for nebulization, 15 mcg/2 mL vial, one vial twice daily [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">
          Indacaterol
         </a>
         – Indacaterol is a once-daily LABA for the treatment of COPD; it has a rapid onset and long duration of action [
         <a href="#rid27">
          27,41-49
         </a>
         ]. Indacaterol is approved by the US Food and Drug Administration (FDA) but is
         <strong>
          not
         </strong>
         currently available in the United States. The dose of indacaterol approved for use in the United States and Canada (75 mcg/capsule; once daily) is lower than the doses approved for Europe (150 and 300 mcg) based on data showing no improvement in efficacy and a possible increase in asthma exacerbations and respiratory-related deaths at the highest doses [
         <a href="#rid50">
          50
         </a>
         ]. Indacaterol is a substrate of CYP3A4 and the P-glycoprotein transporter; however, interactions with agents that inhibit these pathways are not felt to be clinically significant in the prescribed dose range. Indacaterol has been shown to improve lung function and reduce exacerbation rates in patients with COPD [
         <a href="#rid27">
          27,41,48,51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="96482" href="/z/d/drug information/96482.html" rel="external">
          Olodaterol
         </a>
         – Olodaterol, another once-daily LABA with a rapid onset and long duration of action, is delivered as two inhalations (2.5 mcg/actuation) via a soft mist inhaler (SMI) and is approved for the treatment of COPD [
         <a href="#rid52">
          52
         </a>
         ]. It has been shown to improve lung function and quality of life compared with placebo in patients with moderate to severe COPD [
         <a href="#rid52">
          52-55
         </a>
         ]. The soft mist inhaler device can be helpful for certain patients with very poor inspiratory flow or poor hand-breath coordination, typically the elderly or those with advanced COPD. (See
         <a class="medical medical_review" href="/z/d/html/559.html" rel="external">
          "The use of inhaler devices in adults", section on 'Soft mist inhaler technique'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vilanterol
         </strong>
         – Vilanterol is a once-daily LABA with an intermediate onset of action (15 minutes) that has been developed for use in combination inhalers with
         <a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">
          umeclidinium
         </a>
         or
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         furoate [
         <a href="#rid56">
          56
         </a>
         ]. Vilanterol is not available for use as a monotherapy [
         <a href="#rid57">
          57,58
         </a>
         ]. Its use in combination inhalers with either umeclidinium or fluticasone is discussed below. (See
         <a class="local">
          'Comparison with single long-acting bronchodilator'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The potential association of LABA use with cardiac arrhythmias has been closely examined after retrospective studies suggested a possible risk; the data have been generally reassuring regarding LABA safety in patients with COPD. These data are covered in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1454.html" rel="external">
          "Arrhythmias in COPD", section on 'Beta-adrenergic agonists'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1437.html" rel="external">
          "Management of the patient with COPD and cardiovascular disease", section on 'Beta-2 agonists'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4293687569">
         <span class="h3">
          Long-acting muscarinic antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         The LAMAs include
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         ,
         <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">
          aclidinium
         </a>
         ,
         <a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">
          umeclidinium
         </a>
         , and
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         (also called glycopyrronium)  (
         <a class="graphic graphic_table graphicRef122118" href="/z/d/graphic/122118.html" rel="external">
          table 3
         </a>
         ). These agents are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">
          "Role of muscarinic antagonist therapy in COPD"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tiotropium
         </strong>
         –
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          Tiotropium
         </a>
         , the most studied LAMA, is available as a dry powder inhaler (18 mcg/capsule, the contents of which are inhaled once daily) and as an SMI (2.5 mcg/actuation; two inhalations once daily). It improves lung function and decreases dynamic hyperinflation (an effect also seen with other medications), while also decreasing dyspnea and exacerbations [
         <a href="#rid25">
          25,32,59-63
         </a>
         ]. In addition, it improves trough lung function (ie, FEV
         <sub>
          1
         </sub>
         24 hours after the last dose) and reduces hyperinflation, indicating that its effects are long-lasting [
         <a href="#rid64">
          64
         </a>
         ]. Tiotropium may also slow the rate of decline in FEV
         <sub>
          1
         </sub>
         over time [
         <a href="#rid64">
          64-67
         </a>
         ]. Tiotropium is largely excreted by the kidneys; patients with kidney impairment should be monitored for anticholinergic adverse effects, although data on safety are reassuring [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aclidinium
         </strong>
         –
         <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">
          Aclidinium
         </a>
         is available as a dry powder inhaler (400 mcg/actuation, one inhalation twice a day).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Umeclidinium
         </strong>
         –
         <a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">
          Umeclidinium
         </a>
         (62.5 mcg/actuation) is available as a dry powder inhaler, administered one inhalation, once daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycopyrrolate
         </strong>
         –
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          Glycopyrrolate
         </a>
         (also known as glycopyrronium) is available outside the United States as a dry powder inhaler (eg, 50 mcg/capsule used once daily or 25 mcg/capsule used twice daily)  (
         <a class="graphic graphic_table graphicRef105687" href="/z/d/graphic/105687.html" rel="external">
          table 4
         </a>
         ), depending on the region of approval.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Revefenacin
         </strong>
         –
         <a class="drug drug_general" data-topicid="119622" href="/z/d/drug information/119622.html" rel="external">
          Revefenacin
         </a>
         is available as a solution for nebulization. It is administered once daily (175 mcg/3 mL vial, one vial once daily via a standard jet nebulizer).
        </p>
        <p>
        </p>
        <p>
         Older systematic reviews and a case-cohort study suggested possible adverse cardiovascular effects of inhaled muscarinic antagonist therapy. However, data from long-term, placebo-controlled randomized trials have not identified any significant safety issues or increased risk of cardiovascular events in patients with COPD [
         <a href="#rid69">
          69-71
         </a>
         ]. These data are discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">
          "Role of muscarinic antagonist therapy in COPD", section on 'Potential risks'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H71161195">
         <span class="h2">
          Alternate approaches in patients with minimal intermittent symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with infrequent symptoms, it is reasonable to continue only short-acting rescue therapy, as described above.
        </p>
        <p>
         Although some patients may employ regular use of short-acting bronchodilators to relieve symptoms, frequent short-acting bronchodilator use has not been shown to yield the same quality-of-life improvements or reduction in exacerbation rates as long-acting bronchodilators, so it is not a preferred approach.
        </p>
        <p class="headingAnchor" id="H2008009735">
         <span class="h1">
          MORE SYMPTOMATIC PATIENTS AT LOW RISK OF EXACERBATION (GROUP B)
         </span>
        </p>
        <p class="headingAnchor" id="H316235298">
         <span class="h2">
          Use of dual bronchodilator therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with more severe symptoms but low risk for exacerbations, we suggest the use of dual bronchodilator (long-acting beta-agonist/long-acting muscarinic antagonist [LABA-LAMA]) therapy over short-acting bronchodilators or either long-acting bronchodilator alone  (
         <a class="graphic graphic_table graphicRef116691" href="/z/d/graphic/116691.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
         For patients with more severe symptoms, long-acting bronchodilators improve breathlessness and lung function compared with short-acting therapy alone. For example, in one trial comparing the use of
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         (a short-acting muscarinic antagonist) four times daily to daily
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         (a LAMA), tiotropium meaningfully improved dyspnea (31 versus 18 percent) and quality of life (52 versus 35 percent) after one year of therapy, as well as airflow limitation (forced expiratory volume in one second [FEV
         <sub>
          1
         </sub>
         ] +120 mL versus +30 mL) [
         <a href="#rid60">
          60
         </a>
         ]. Similarly, compared with placebo, patients using the LABAs
         <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">
          indacaterol
         </a>
         and
         <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">
          salmeterol
         </a>
         were more likely to have meaningful improvement in quality of life (53 and 49 percent versus 38 percent) and lung function (FEV
         <sub>
          1
         </sub>
         +150 mL and +90 mL versus -30 mL) after 26 weeks of therapy [
         <a href="#rid51">
          51
         </a>
         ]. Additional placebo-controlled trials of individual agents have generally established the efficacy of long-acting bronchodilators in terms of both pulmonary function and symptomatic improvement. These data are discussed separately. (See
         <a class="local">
          'Dosing and efficacy of individual agents'
         </a>
         above.)
        </p>
        <p>
         Clinical trials in support of combined LAMA-LABA therapy for patients with severe breathlessness generally show added value to dual bronchodilation over single-agents for relief of dyspnea, although results vary depending on the specific agents and end-points [
         <a href="#rid6">
          6,23,24,72-81
         </a>
         ]. Nearly all trials demonstrate improvements in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) with dual compared with individual long-acting bronchodilator therapy, but not always with clinically significant changes in breathlessness or quality of life.
        </p>
        <p>
         Use of fixed-dose LAMA-LABA combinations, rather than two separate inhalers, may be preferred due to a potential for improved adherence, which may lead to improved outcomes and reduced costs [
         <a href="#rid82">
          82,83
         </a>
         ]. In general, dual bronchodilator therapies do not show any additional risks in their safety profiles as compared with their monotherapies.
        </p>
        <p>
         A systematic review and meta-analysis of 10 trials (10,894 participants) that assessed combination bronchodilator therapy with
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         (LAMA) plus a LABA (
         <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">
          salmeterol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">
          formoterol
         </a>
         , or
         <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">
          indacaterol
         </a>
         ) found a slightly better quality of life and a small increase in the postbronchodilator FEV
         <sub>
          1
         </sub>
         with the combination compared with either LAMA or LABA alone [
         <a href="#rid23">
          23
         </a>
         ]. No difference was noted in hospital admissions, mortality, and serious adverse events.
        </p>
        <p>
         Each of the following single-inhaler combinations improve FEV
         <sub>
          1
         </sub>
         compared with their single-agent components [
         <a href="#rid74">
          74-77,79,84-92
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tiotropium-olodaterol
         </strong>
         – Combination
         <a class="drug drug_general" data-topicid="101635" href="/z/d/drug information/101635.html" rel="external">
          tiotropium-olodaterol
         </a>
         (2.5 mcg/2.5 mcg per actuation, two inhalations once daily) is delivered via soft mist inhaler (SMI).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Umeclidinium-vilanterol
         </strong>
         –
         <a class="drug drug_general" data-topicid="91900" href="/z/d/drug information/91900.html" rel="external">
          Umeclidinium-vilanterol
         </a>
         (62.5 mcg/25 mcg per actuation) is a dry powder inhaler used at a dose of one inhalation daily for COPD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="94783" href="/z/d/drug information/94783.html" rel="external">
          Glycopyrronium-indacaterol
         </a>
         – A once-daily dry powder inhaler containing the combination of glycopyrronium-indacaterol (50 mcg/110 mcg per capsule) is available in Canada, Europe, and elsewhere [
         <a href="#rid88">
          88
         </a>
         ]. A lower dose preparation is approved for use in the United States based on evidence of efficacy compared with its components [
         <a href="#rid89">
          89
         </a>
         ], but is not being manufactured [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As with
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         , glycopyrronium-containing therapies are excreted by the kidney and their use in patients with severe kidney impairment should be based on expected benefits versus potential risks [
         <a href="#rid94">
          94
         </a>
         ]. Patients with kidney impairment should be monitored for anticholinergic adverse effects. (See
         <a class="local">
          'Long-acting muscarinic antagonists'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycopyrrolate-formoterol
         </strong>
         – A combination metered dose inhaler containing
         <a class="drug drug_general" data-topicid="107880" href="/z/d/drug information/107880.html" rel="external">
          glycopyrrolate-formoterol
         </a>
         (9 mcg/4.8 mcg per actuation) is available for the treatment of COPD at a dose of two inhalations twice daily [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aclidinium-formoterol
         </strong>
         –
         <a class="drug drug_general" data-topicid="104071" href="/z/d/drug information/104071.html" rel="external">
          Aclidinium-formoterol
         </a>
         (400 mcg/12 mcg per actuation) is available as a combination dry powder inhaler administered as one inhalation twice daily.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1423997921">
         <span class="h2">
          Alternative approaches
         </span>
        </p>
        <p class="headingAnchor" id="H187577517">
         <span class="h3">
          Group B patients who cannot use LAMA-LABA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For Group B patients with COPD who are unable to take a LAMA-LABA combination therapy due to cost, availability, or side effects, either a LAMA or a LABA alone are reasonable alternatives. (See
         <a class="local">
          'Dosing and efficacy of individual agents'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3111911136">
         <span class="h3">
          Patients with possible concomitant asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with COPD and asthma (also known as COPD-A or asthma-COPD overlap [ACO]), symptoms and exacerbations may be better controlled with the addition of an inhaled glucocorticoid (ie, inhaled corticosteroids [ICS]) to their therapy. Although combination therapy with a LABA plus ICS may be used in these patients, we prefer LABA-LAMA-ICS therapy due to the added benefits of dual bronchodilation for COPD along with the ICS for asthma control. Features that can be used to identify patients with ACO are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/122856.html" rel="external">
          "Asthma and COPD overlap (ACO)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1171219070">
         <span class="h1">
          PATIENTS AT HIGH RISK OF EXACERBATION (GROUP E)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among the Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups, patients with frequent exacerbations (Group E) are at the highest risk for hospitalization and death due to COPD. Because of this, they require the use of potent combination therapies upfront to reduce the risk of these adverse outcomes. Many patients will improve with dual bronchodilator therapy, which avoids potential adverse effects from inhaled glucocorticoids (ie, inhaled corticosteroids [ICS]).
        </p>
        <p class="headingAnchor" id="H520210716">
         <span class="h2">
          Dual bronchodilator therapy, in most cases
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, for patients initiating COPD therapy with a high risk of future exacerbations, we suggest initial treatment with combination long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist (LABA) therapy rather than using either agent alone or automatic initiation of inhaled glucocorticoids  (
         <a class="graphic graphic_table graphicRef116691" href="/z/d/graphic/116691.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2282748963">
         <span class="h3">
          Comparison with single long-acting bronchodilator
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific data in support of dual bronchodilator therapy over single bronchodilators in patients with exacerbations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of 10 trials assessing combination bronchodilator therapy with
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         found small symptomatic improvements with combination therapy compared with individual therapy (described above), as well as an improvement in exacerbations with tiotropium-LABA therapy compared with LABA alone (odds ratio [OR] 0.80, 95% CI 0.69-0.93) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis including indirect comparisons (ie, network analysis) of 26 studies and over 30,000 participants with a history of recent exacerbation suggested a reduction in moderate to severe exacerbations compared with LAMA (hazard ratio [HR] 0.87, 95% CI 0.78-0.99) or LABA alone (HR 0.70, 95% CI 0.61-0.8) [
         <a href="#rid24">
          24
         </a>
         ]. There was also a general trend towards a greater improvement in symptom and quality-of-life scores with the combination therapies compared with monotherapies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of
         <a class="drug drug_general" data-topicid="91900" href="/z/d/drug information/91900.html" rel="external">
          umeclidinium-vilanterol
         </a>
         reported that the number of patients with at least one COPD exacerbation was less in the combination group compared with the individual agents (vilanterol [RR 0.72, 95% CI 0.54-0.95] and
         <a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">
          umeclidinium
         </a>
         [RR 0.74, 95% CI 0.54-0.98]); however, umeclidinium-vilanterol was not different compared with
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         or
         <a class="drug drug_general" data-topicid="8730" href="/z/d/drug information/8730.html" rel="external">
          fluticasone-salmeterol
         </a>
         [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Additional evidence supports benefit for dual bronchodilator therapy for the improvement of dyspnea in patients with severe symptoms. (See
         <a class="local">
          'Use of dual bronchodilator therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1979174482">
         <span class="h3">
          Comparison with LABA-ICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both LABA-LAMA therapy and LABA-ICS combinations have demonstrated reductions in exacerbations compared with single bronchodilator therapy. The preference for using LAMA-LABA therapy over a LABA-ICS combination is largely based on evidence of improved lung function, better control of mild exacerbations, and fewer episodes of pneumonia (and other ICS adverse effects), although improvement in symptoms varies among studies [
         <a href="#rid6">
          6,24,96-98
         </a>
         ]. Although there is a small signal towards improved mortality in patients receiving LABA-ICS, this effect was driven by patients with frequent exacerbations and eosinophilia despite dual therapy [
         <a href="#rid99">
          99
         </a>
         ]. We believe this group is more appropriate for LABA-LAMA-ICS treatment, rather than either LABA-LAMA or LABA-ICS. (See
         <a class="local">
          'Alternative approaches'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Exacerbations on LAMA-LABA therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Exacerbations on LABA-ICS'
         </a>
         .)
        </p>
        <p>
         In one multicenter trial,
         <a class="drug drug_general" data-topicid="94783" href="/z/d/drug information/94783.html" rel="external">
          glycopyrronium-indacaterol
         </a>
         (50 microg-110 microg, once daily) was compared with
         <a class="drug drug_general" data-topicid="8730" href="/z/d/drug information/8730.html" rel="external">
          fluticasone-salmeterol
         </a>
         (500 microg-50 microg, twice daily) in 3362 patients with moderate to severe COPD characterized by higher dyspnea scores and a history of at least one moderate to severe exacerbation in the previous year [
         <a href="#rid96">
          96
         </a>
         ]. Over the 52-week trial, glycopyrronium-indacaterol reduced the rate of mild to severe COPD exacerbations by 11 percent compared with fluticasone-salmeterol (rate ratio 0.89, 95% CI 0.83-0.96). Importantly, patients with a history of two or more moderate exacerbations or one hospitalization in the previous year had similar exacerbation rates in the two treatment arms. Glycopyrronium-indacaterol was associated with slightly fewer episodes of pneumonia (3.2 percent) compared with fluticasone-salmeterol (4.8 percent).
        </p>
        <p class="headingAnchor" id="H1699656468">
         <span class="h2">
          Alternative approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selected patients with COPD and a high risk of exacerbations may benefit from alternative therapeutic approaches.
        </p>
        <p class="headingAnchor" id="H1627042693">
         <span class="h3">
          Group E patients presenting with elevated eosinophil counts or hospitalization
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who have frequent COPD exacerbations (ie, ≥2/year) and blood eosinophils ≥300 cells/microL, we agree with the GOLD that initial treatment with dual bronchodilator therapy plus an ICS is reasonable initial therapy based on potential benefits of ICS in this population. Additional information on the use of eosinophils to guide use of ICS is detailed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Blood eosinophils, inhaled corticosteroids, and exacerbations'
         </a>
         .)
        </p>
        <p>
         Although not as well-studied, LAMA-LABA-ICS therapy may also be appropriate in patients hospitalized for a COPD exacerbation needing initial medical management, as these patients are at high risk for additional COPD-associated hospitalizations and mortality.
        </p>
        <p>
         Patients with greater numbers of exacerbations, severe exacerbations leading to hospitalization, and higher blood eosinophil levels demonstrate greater reductions in exacerbations and improvement in lung function plus a likely small improvement in mortality in trials of LAMA-LABA-ICS versus other therapeutic approaches, including LAMA-LABA therapy [
         <a href="#rid99">
          99-107
         </a>
         ]. However, LAMA-LABA-ICS therapy has not been studied specifically as an initial treatment option in clinical trials. Data supporting the use of LAMA-LABA-ICS as follow-up therapy in patients with frequent exacerbations are detailed separately. (See
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Persistent exacerbations with or without dyspnea'
         </a>
         .)
        </p>
        <p>
         Adverse effects associated with ICS (eg, pneumonia, oropharyngeal candidiasis, cataracts, and increased risk of osteoporosis) are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H101543484">
         <span class="h3">
          Group E patients who cannot use LAMA-LABA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For Group E patients with COPD who are unable to use a LAMA-LABA combination therapy due to cost, availability, or side effects, either single bronchodilator therapy or LABA-ICS therapy may be of benefit. Combined LAMA and ICS therapy has not been investigated.
        </p>
        <p>
         Either a LAMA or a LABA alone has been shown to improve symptoms and reduce exacerbation rates compared with placebo. (See
         <a class="local">
          'Dosing and efficacy of individual agents'
         </a>
         above.)
        </p>
        <p>
         For those who cannot use a LAMA, combination LABA-ICS therapy  (
         <a class="graphic graphic_table graphicRef122859" href="/z/d/graphic/122859.html" rel="external">
          table 6
         </a>
         ) is frequently more effective than LABA alone. In patients with moderate to severe airflow limitation and frequent exacerbations, combination LABA-ICS therapy significantly improves outcomes compared with placebo, LABA alone, or ICS alone [
         <a href="#rid33">
          33,108-116
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For example, in the Toward a Revolution in COPD Health (TORCH) trial of 6112 patients with moderate to severe COPD,
         <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">
          salmeterol
         </a>
         plus
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         significantly improved the secondary end points of lung function, health status, and the rate of exacerbations compared with placebo, salmeterol alone, or fluticasone alone [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, in a pooled analysis of two trials that compared combinations of vilanterol-fluticasone with vilanterol alone in 3255 patients with COPD, vilanterol 25 mcg with
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         100 or 200 mcg modestly reduced the yearly exacerbation rates more than vilanterol alone (RR 0.79, 95% CI 0.64-0.97, RR 0.69, 95% CI 0.56-0.85, respectively) [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Multiple analyses have shown that blood eosinophil counts strongly correlate with the effectiveness of ICS when added to LABA therapy in preventing future COPD exacerbations [
         <a href="#rid102">
          102,103,117
         </a>
         ]. Minimal effects of ICS are seen in patients with lower eosinophil counts, with incrementally increasing effects at higher levels [
         <a href="#rid104">
          104
         </a>
         ]. Although precise cutoffs by their nature are arbitrary, patients with ≥300 cells/microL have consistent benefits from ICS, whereas patients with lower eosinophil counts (&lt;100 cells/microL) may be at increased risk for pneumonia compared with other COPD patients on ICS therapy [
         <a href="#rid105">
          105,106
         </a>
         ]. The role of eosinophil counts in managing therapy is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Blood eosinophils, inhaled corticosteroids, and exacerbations'
         </a>
         .)
        </p>
        <p>
         Adverse effects associated with ICS (eg, pneumonia, oropharyngeal candidiasis, cataracts, and increased risk of osteoporosis) are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H305365038">
         <span class="h3">
          Patients with possible concomitant asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with exacerbations and both COPD and asthma (also known as COPD-A and asthma-COPD overlap [ACO]) may also benefit from LABA plus ICS rather than with dual bronchodilator therapy. In patients with more severe symptoms or hospitalizations due to exacerbation, we prefer LAMA-LABA-ICS therapy due to the added benefits of dual bronchodilation for COPD. Features that can be used to identify patients with COPD and asthma are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/122856.html" rel="external">
          "Asthma and COPD overlap (ACO)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H85895942">
         <span class="h1">
          OBSOLETE APPROACHES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhaled glucocorticoids have been used for decades as part of COPD therapy based on their efficacy in treating airway and systemic inflammation [
         <a href="#rid118">
          118-123
         </a>
         ]; however, they are no longer recommended for use without accompanying long-acting bronchodilator therapy. (See
         <a class="medical medical_review" href="/z/d/html/1449.html" rel="external">
          "Role of inhaled glucocorticoid therapy in stable COPD"
         </a>
         .)
        </p>
        <p>
         The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy includes
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         as an inexpensive, but not recommended, alternative to the above described long-acting inhaled bronchodilators [
         <a href="#rid6">
          6
         </a>
         ]. We also do not recommend the substitution of theophylline for long-acting bronchodilator therapies unless these agents are unavailable. Use of theophylline in refractory COPD is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">
          "Management of refractory chronic obstructive pulmonary disease", section on 'Theophylline, monitored by drug levels'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H168451477">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">
          "Society guideline links: Chronic obstructive pulmonary disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15430.html" rel="external">
          "Patient education: Chronic obstructive pulmonary disease (COPD) (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16192.html" rel="external">
          "Patient education: Shortness of breath (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16113.html" rel="external">
          "Patient education: How to use your metered dose inhaler (adults) (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16114.html" rel="external">
          "Patient education: How to use your dry powder inhaler (adults) (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/116647.html" rel="external">
          "Patient education: How to use your soft mist inhaler (adults) (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/85724.html" rel="external">
          "Patient education: Medicines for COPD (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/115180.html" rel="external">
          "Patient education: Inhaled corticosteroid medicines (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4649.html" rel="external">
          "Patient education: Chronic obstructive pulmonary disease (COPD) (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4647.html" rel="external">
          "Patient education: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/369.html" rel="external">
          "Patient education: Inhaler techniques in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H40">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph utd-adt-cnt utd-adt-pathwys">
          ●
         </span>
         <strong>
          Assessing symptoms and exacerbation risk to guide therapy
         </strong>
         – As a guide for initial pharmacologic management, patients with stable COPD can be categorized according to the severity of symptoms and the risk of future exacerbations  (
         <a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">
          algorithm 1
         </a>
         ). Symptoms should be assessed using a validated instrument; the modified Medical Research Council (mMRC) dyspnea scale (
         <a class="calc calc_professional" href="/z/d/html/142813.html" rel="external">
          calculator 1
         </a>
         ) or the COPD Assessment Test (CAT) (
         <a class="calc calc_professional" href="/z/d/html/142838.html" rel="external">
          calculator 2
         </a>
         ) are preferred. Exacerbation risk is based on the patient’s history of exacerbations in the past year; two or more exacerbations requiring systemic glucocorticoids or any hospitalization for COPD exacerbation indicate a greater risk of future exacerbations. (See
         <a class="local">
          'Assessing disease pattern and severity'
         </a>
         above.)
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120055">
          (Related Pathway(s):
          <a class="utd-content-120055" href="/pathway/120055?topicRef=1447&amp;source=see_link">
           Chronic obstructive pulmonary disease: Severity assessment and selection of initial therapy in adults
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – The mainstays of therapy for stable COPD are inhaled bronchodilators (beta-agonists and muscarinic antagonists, usually long-acting) given alone, in combination, or with the addition of inhaled glucocorticoids. Nonpharmacologic therapies (eg, smoking cessation, pulmonary rehabilitation, vaccination, nutrition) should be initiated along with pharmacotherapy. (See
         <a class="local">
          'General principles'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/120326.html" rel="external">
          "Stable COPD: Overview of management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Short-acting bronchodilator for quick relief
         </strong>
         – For all patients with COPD, we provide a short-acting bronchodilator (eg, beta-agonist, muscarinic antagonist, or combination) for use as needed for relief of intermittent increases in dyspnea. For patients on a long-acting muscarinic antagonist (LAMA), a short-acting beta-agonist (SABA) is generally used for quick relief of COPD symptoms. For patients not on a LAMA, a SABA or a combination SABA plus a short-acting muscarinic antagonist (SAMA) should be prescribed for rescue use. (See
         <a class="local">
          'Rescue bronchodilator therapy for all patients'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">
          "COPD exacerbations: Management", section on 'Home or office management of COPD exacerbations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial pharmacologic therapy
         </strong>
         – Initial therapy is guided by the severity of symptoms and risk of future exacerbations  (
         <a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Group A
         </strong>
         – For patients who are less symptomatic (mMRC grade &lt;2 (
         <a class="calc calc_professional" href="/z/d/html/142813.html" rel="external">
          calculator 1
         </a>
         ) or CAT score &lt;10 (
         <a class="calc calc_professional" href="/z/d/html/142838.html" rel="external">
          calculator 2
         </a>
         )) and at low risk of exacerbation (zero to one exacerbation per year), we suggest the use of a long-acting bronchodilator rather than short-acting bronchodilators alone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We suggest using a LAMA  (
         <a class="graphic graphic_table graphicRef122118" href="/z/d/graphic/122118.html" rel="external">
          table 3
         </a>
         ) rather than a long-acting beta-agonist (LABA) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); however, a once daily LABA is an appropriate alternative depending on the patient’s symptoms and risks for medication adverse effects  (
         <a class="graphic graphic_table graphicRef122116" href="/z/d/graphic/122116.html" rel="external">
          table 2
         </a>
         ). Short-acting therapies alone are also reasonable in patients with only infrequent intermittent dyspnea. (See
         <a class="local">
          'Less symptomatic patients at low risk of exacerbation (Group A)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Group B
         </strong>
         – For patients who are more symptomatic (mMRC grade ≥2 (
         <a class="calc calc_professional" href="/z/d/html/142813.html" rel="external">
          calculator 1
         </a>
         ) or CAT score ≥10 (
         <a class="calc calc_professional" href="/z/d/html/142838.html" rel="external">
          calculator 2
         </a>
         )), but at low risk of exacerbation based on their past history of exacerbations (zero to one exacerbation per year), we suggest regular use of long-acting inhaled bronchodilators rather than short-acting agents (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ), preferably dual bronchodilator (LAMA-LABA) therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Use of fixed-dose LAMA-LABA combinations, rather than two separate inhalers, may be preferred due to a potential for improved adherence, which may lead to improved outcomes and reduced costs  (
         <a class="graphic graphic_table graphicRef116691" href="/z/d/graphic/116691.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Dosing and efficacy of individual agents'
         </a>
         above and
         <a class="local">
          'More symptomatic patients at low risk of exacerbation (Group B)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Group E
         </strong>
         – For patients with a high risk of exacerbation (ie, ≥2 exacerbations per year or one or more exacerbation leading to hospitalization), we suggest initial treatment with LAMA-LABA therapy rather than either bronchodilator alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients with hospitalization due to exacerbation or highly elevated blood eosinophils (≥300 cells/microL), we suggest upfront LAMA-LABA-ICS therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Patients at high risk of exacerbation (Group E)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Possible asthma-COPD overlap
         </strong>
         – Patients with asthma-COPD overlap (ACO, also known as COPD-A) may benefit from earlier initiation of inhaled glucocorticoids than recommended for typical patients with COPD. The diagnosis and management of ACO is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/122856.html" rel="external">
          "Asthma and COPD overlap (ACO)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up adjustment
         </strong>
         – Pharmacologic therapy is adjusted at follow-up visits based on the response to therapy  (
         <a class="graphic graphic_table graphicRef122795" href="/z/d/graphic/122795.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ford ES, Croft JB, Mannino DM, et al. COPD surveillance--United States, 1999-2011. Chest 2013; 144:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burney P, Jithoo A, Kato B, et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty--a BOLD analysis. Thorax 2014; 69:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford ES, Mannino DM, Wheaton AG, et al. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. Chest 2013; 143:1395.
          </a>
         </li>
         <li class="breakAll">
          Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/products/databriefs/db328.htm (Accessed on May 28, 2019).
         </li>
         <li class="breakAll">
          World Health Organization. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (Accessed on May 28, 2019).
         </li>
         <li class="breakAll">
          Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org www.goldcopd.org (Accessed on November 16, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores. BMC Pulm Med 2011; 11:42.
          </a>
         </li>
         <li class="breakAll">
          COPD Assessment Test (CAT) for outside the United States. http://www.catestonline.org/ (Accessed on February 06, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J 2014; 44:873.
          </a>
         </li>
         <li class="breakAll">
          COPD Assessment Test (CAT). http://www.catestonline.org (Accessed on October 23, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ram FS, Sestini P. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003; 58:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook D, Guyatt G, Wong E, et al. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med 1996; 100:11S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou Y, Zhong NS, Li X, et al. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. N Engl J Med 2017; 377:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; :CD009157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farne HA, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; :CD008989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev 2018; 12:CD012620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013; 68:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013; 173:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290:2301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cazzola M, Donner CF. Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease. Drugs 2000; 60:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; :CD010177.
          </a>
         </li>
         <li class="breakAll">
          Salmeterol product label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d9728e-6b5c-4aee-bfb0-745e542ed2e4 (Accessed on March 06, 2023).
         </li>
         <li class="breakAll">
          Product monograph https://pdf.hres.ca/dpd_pm/00044980.PDF (Accessed on March 06, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donohue JF, Hanania NA, Make B, et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest 2014; 146:1531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011; 140:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011; 105:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011; 105:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerwin EM, Gotfried MH, Lawrence D, et al. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther 2011; 33:1974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011; 38:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Indacterol (Arcapta Neohaler) for COPD. Med Lett Drugs Ther 2012; 54:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang FM, Liang ZA, Zheng QL, et al. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review. Lung 2013; 191:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 1:CD010139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seth HD, Sultan S, Gotfried MH. Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease. J Thorac Dis 2013; 5:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chowdhury BA, Seymour SM, Michele TM, et al. The risks and benefits of indacaterol--the FDA's review. N Engl J Med 2011; 365:2247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joos GF, Aumann JL, Coeck C, et al. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease. Respir Med 2015; 109:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maleki-Yazdi MR, Beck E, Hamilton AL, et al. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease. Respir Med 2015; 109:596.
          </a>
         </li>
         <li class="breakAll">
          Vilanteral drug label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96428df1-ea05-431a-98d3-1ec2c4b63878 (Accessed on March 06, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther 2013; 26:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012; 142:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casaburi R, Briggs DD Jr, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000; 118:1294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004; 1:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaForce C, Derom E, Bothner U, et al. Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies. Int J Chron Obstruct Pulmon Dis 2018; 13:1819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise RA, Chapman KR, Scirica BM, et al. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. JAMA 2019; 321:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369:1491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015; 45:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigo GJ, Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review. Chest 2014; 146:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res 2015; 16:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigo GJ, Neffen H. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD. Chest 2015; 148:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horita N, Nagashima A, Kaneko T. Long-Acting β-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD. JAMA 2017; 318:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ni H, Moe S, Soe Z, et al. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2018; 12:CD011594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maltais F, Aumann JL, Kirsten AM, et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Respir J 2019; 53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res 2019; 20:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu AP, Guérin A, de Leon DP, et al. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med 2011; 105:1861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ 2011; 14:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med 2015; 109:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013; 107:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014; 145:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med 2014; 108:1752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frampton JE. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs 2014; 74:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2015; 192:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez FJ, Rabe KF, Ferguson GT, et al. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest 2017; 151:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014; 14:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014; 15:123.
          </a>
         </li>
         <li class="breakAll">
          Utibron neohaler prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/utibron.pdf (Accessed on November 02, 2015).
         </li>
         <li class="breakAll">
          European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Ultibro Breezhaler. International non-proprietary names: indacaterol /glycopyrronium
bromide, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002679/WC500151257.pdf (Accessed on March 28, 2014).
         </li>
         <li class="breakAll">
          Bevespi aerosphere prescribing information. http://www.azpicentral.com/bevespi/bevespi_pi.pdf (Accessed on April 28, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016; 374:2222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuda N, Horita N, Kaneko A, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2023; 6:CD012066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Deng ZX, Sun J, et al. Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD: A Meta-analysis of 60 Randomized Controlled Trials. Chest 2023; 163:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med 2020; 383:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 2018; 378:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh D, Bafadhel M, Brightling CE, et al. Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2020; 202:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med 2016; 4:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis. Am J Respir Crit Care Med 2020; 201:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017; 389:1919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; :CD006829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharafkhaneh A, Southard JG, Goldman M, et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012; 106:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis 2012; 7:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. N Engl J Med 2016; 375:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med 2013; 107:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018; 6:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozol D, Aysan T, Solak ZA, et al. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med 2005; 99:1494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bart G. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med 2009; 151:218; author reply 218.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1447 Version 89.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23619732" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : COPD surveillance--United States, 1999-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24353008" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty--a BOLD analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23715520" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23715520" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23715520" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23715520" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21835018" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21835018" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24993906" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The COPD assessment test: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24993906" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The COPD assessment test: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19720809" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Development and first validation of the COPD Assessment Test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20843247" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Susceptibility to exacerbation in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8181328" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12832670" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11208630" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8610712" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10084468" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10208193" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28877027" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21428765" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972134" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24461613" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26490945" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30521694" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12114338" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23042705" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20463178" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23689820" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14600189" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Contemporary management of chronic obstructive pulmonary disease: scientific review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9266866" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Salmeterol reduces dyspnea and improves lung function in patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10983735" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16537846" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17314337" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11316640" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9105068" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Quality of life changes in COPD patients treated with salmeterol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16443706" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24127118" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Long-acting beta2-agonists for chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24127118" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Long-acting beta2-agonists for chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24127118" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Long-acting beta2-agonists for chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25451347" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21349928" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Long-term safety and efficacy of indacaterol, a long-actingβ₂-agonist, in subjects with COPD: a randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21227674" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21367594" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22177371" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Efficacy and tolerability of indacaterol 75μg once daily in patients aged≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21622587" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22538621" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Indacterol (Arcapta Neohaler) for COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23306410" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25575340" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24409359" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22168640" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The risks and benefits of indacaterol--the FDA's review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20693243" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25776199" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-actingβ2-agonist, in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25045258" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat®versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24966672" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Efficacy and safety of olodaterol once daily delivered via Respimat®in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25829298" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-actingβ2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25829298" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-actingβ2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23232038" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22241764" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The efficacy and safety of the novel long-actingβ2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11866001" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11871363" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16507855" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The effect of tiotropium on exacerbations and airflow in patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11083677" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16144890" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15218994" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15649848" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17136995" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19716598" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29910611" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Long-term safety of tiotropium/olodaterol Respimat®in patients with moderate-to-very severe COPD and renal impairment in the TONADO®studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18836213" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31063575" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23992515" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Tiotropium Respimat inhaler and the risk of death in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16055868" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19229704" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25573406" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24556877" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26233481" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25798635" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28973232" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Long-Actingβ-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30536566" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30655277" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31666084" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21807487" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21679019" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26320402" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23830094" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24385182" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25458157" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24604791" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26177074" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27916620" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25404569" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25756831" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25756831" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25756831" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25756831" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27181606" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18403672" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37276335" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35921883" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD: A Meta-analysis of 60 Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32579807" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29668352" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29429593" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25878028" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32186896" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27460163" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31922913" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28385353" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17053207" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972099" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17916806" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18511702" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22033040" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22334769" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27593504" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23332861" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Fluticasone furoate/vilanterol (100/25; 200/25μg) improves lung function in COPD: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24429127" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29331313" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16143583" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : C-reactive protein in patients with COPD, control smokers and non-smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15707484" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15946834" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15229100" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17301099" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19652193" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Concerns about consensus guidelines for QTc interval screening in methadone treatment.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
